• Je něco špatně v tomto záznamu ?

Expert opinion on NSCLC small specimen biomarker testing - Part 1: Tissue collection and management

F. Penault-Llorca, KM. Kerr, P. Garrido, E. Thunnissen, E. Dequeker, N. Normanno, SJ. Patton, J. Fairley, J. Kapp, D. de Ridder, A. Ryška, H. Moch

. 2022 ; 481 (3) : 335-350. [pub] 20220720

Jazyk angličtina Země Německo

Typ dokumentu časopisecké články, přehledy

Perzistentní odkaz   https://www.medvik.cz/link/bmc22024700
E-zdroje Online Plný text

NLK ProQuest Central od 2003-01-01 do Před 1 rokem
Medline Complete (EBSCOhost) od 2011-01-01 do Před 1 rokem
Nursing & Allied Health Database (ProQuest) od 2003-01-01 do Před 1 rokem
Health & Medicine (ProQuest) od 2003-01-01 do Před 1 rokem

Odkazy

PubMed 35857102
DOI 10.1007/s00428-022-03343-2
Knihovny.cz E-zdroje

Biomarker testing is crucial for treatment selection in advanced non-small cell lung cancer (NSCLC). However, the quantity of available tissue often presents a key constraint for patients with advanced disease, where minimally invasive tissue biopsy typically returns small samples. In Part 1 of this two-part series, we summarise evidence-based recommendations relating to small sample processing for patients with NSCLC. Generally, tissue biopsy techniques that deliver the greatest quantity and quality of tissue with the least risk to the patient should be selected. Rapid on-site evaluation can help to ensure sufficient sample quality and quantity. Sample processing should be managed according to biomarker testing requirements, because tissue fixation methodology influences downstream nucleic acid, protein and morphological analyses. Accordingly, 10% neutral buffered formalin is recommended as an appropriate fixative, and the duration of fixation is recommended not to exceed 24-48 h. Tissue sparing techniques, including the 'one biopsy per block' approach and small sample cutting protocols, can help preserve tissue. Cytological material (formalin-fixed paraffin-embedded [FFPE] cytology blocks and non-FFPE samples such as smears and touch preparations) can be an excellent source of nucleic acid, providing either primary or supplementary patient material to complete morphological and molecular diagnoses. Considerations on biomarker testing, reporting and quality assessment are discussed in Part 2.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc22024700
003      
CZ-PrNML
005      
20221031100330.0
007      
ta
008      
221017s2022 gw f 000 0|eng||
009      
AR
024    7_
$a 10.1007/s00428-022-03343-2 $2 doi
035    __
$a (PubMed)35857102
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a gw
100    1_
$a Penault-Llorca, Frédérique $u University Clermont Auvergne, INSERM U1240, Centre Jean Perrin, Clermont-Ferrand, France
245    10
$a Expert opinion on NSCLC small specimen biomarker testing - Part 1: Tissue collection and management / $c F. Penault-Llorca, KM. Kerr, P. Garrido, E. Thunnissen, E. Dequeker, N. Normanno, SJ. Patton, J. Fairley, J. Kapp, D. de Ridder, A. Ryška, H. Moch
520    9_
$a Biomarker testing is crucial for treatment selection in advanced non-small cell lung cancer (NSCLC). However, the quantity of available tissue often presents a key constraint for patients with advanced disease, where minimally invasive tissue biopsy typically returns small samples. In Part 1 of this two-part series, we summarise evidence-based recommendations relating to small sample processing for patients with NSCLC. Generally, tissue biopsy techniques that deliver the greatest quantity and quality of tissue with the least risk to the patient should be selected. Rapid on-site evaluation can help to ensure sufficient sample quality and quantity. Sample processing should be managed according to biomarker testing requirements, because tissue fixation methodology influences downstream nucleic acid, protein and morphological analyses. Accordingly, 10% neutral buffered formalin is recommended as an appropriate fixative, and the duration of fixation is recommended not to exceed 24-48 h. Tissue sparing techniques, including the 'one biopsy per block' approach and small sample cutting protocols, can help preserve tissue. Cytological material (formalin-fixed paraffin-embedded [FFPE] cytology blocks and non-FFPE samples such as smears and touch preparations) can be an excellent source of nucleic acid, providing either primary or supplementary patient material to complete morphological and molecular diagnoses. Considerations on biomarker testing, reporting and quality assessment are discussed in Part 2.
650    _2
$a biologické markery $7 D015415
650    12
$a nemalobuněčný karcinom plic $x diagnóza $x patologie $7 D002289
650    _2
$a znalecký posudek $7 D005104
650    _2
$a fixativa $7 D005404
650    _2
$a formaldehyd $7 D005557
650    _2
$a lidé $7 D006801
650    12
$a nádory plic $x diagnóza $x patologie $7 D008175
650    12
$a nukleové kyseliny $7 D009696
650    _2
$a zalévání tkání do parafínu $7 D016612
650    _2
$a fixace tkání $x metody $7 D016707
655    _2
$a časopisecké články $7 D016428
655    _2
$a přehledy $7 D016454
700    1_
$a Kerr, Keith M $u Department of Pathology, Aberdeen University Medical School and Aberdeen Royal Infirmary, Aberdeen, UK
700    1_
$a Garrido, Pilar $u Medical Oncology Department, Hospital Universitario Ramón Y Cajal, University of Alcalá, Madrid, Spain
700    1_
$a Thunnissen, Erik $u Amsterdam University Medical Center, VU Medical Center, Amsterdam, the Netherlands
700    1_
$a Dequeker, Elisabeth $u Department of Public Health, Biomedical Quality Assurance Research Unit, Campus Gasthuisberg, University Leuven, Leuven, Belgium
700    1_
$a Normanno, Nicola $u Cell Biology and Biotherapy Unit, Istituto Nazionale Tumori "Fondazione Giovanni Pascale" IRCCS, Naples, Italy
700    1_
$a Patton, Simon J $u EMQN CIC, Manchester, UK
700    1_
$a Fairley, Jenni $u GenQA, Edinburgh, UK
700    1_
$a Kapp, Joshua $u Amgen (Europe) GmbH, Rotkreuz, Switzerland
700    1_
$a de Ridder, Daniëlle $u Amgen BV, Breda, the Netherlands
700    1_
$a Ryška, Aleš $u Department of Pathology, Charles University Medical Faculty Hospital, Hradec Králové, Czech Republic
700    1_
$a Moch, Holger $u Department of Pathology and Molecular Pathology, University Hospital Zurich and University of Zurich, Zurich, Switzerland. holger.moch@usz.ch $1 https://orcid.org/http://orcid.org/0000000279862839
773    0_
$w MED00004660 $t Virchows Archiv $x 1432-2307 $g Roč. 481, č. 3 (2022), s. 335-350
856    41
$u https://pubmed.ncbi.nlm.nih.gov/35857102 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20221017 $b ABA008
991    __
$a 20221031100328 $b ABA008
999    __
$a ok $b bmc $g 1854439 $s 1175990
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2022 $b 481 $c 3 $d 335-350 $e 20220720 $i 1432-2307 $m Virchows Archiv $n Virchows Arch $x MED00004660
LZP    __
$a Pubmed-20221017
Zpět

Najít záznam

Citační ukazatele

    Možnosti archivace